Related Experiment Video
Updated: Dec 23, 2025
12:58
Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
Published on: May 10, 2017
9.7K
Blastic Plasmacytoid Dendritic Cell Neoplasm in Children
Yixian Li1, Victoria Sun2, Weili Sun3
1Pediatric Hematology, Oncology, Marrow and Blood Cell Transplantation, Children's Hospital at Montefiore, 3411 Wayne Avenue, 9th Floor, Bronx, NY 10467, USA.
Hematology/Oncology Clinics of North America
|April 28, 2020
Summary
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare cancer. New targeted therapies, like anti-CD123, show promise for improving patient response rates.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy.
- It originates from plasmacytoid dendritic cells and primarily affects older adults, though it can occur at any age.
- Typical presentations include skin lesions, with or without bone marrow involvement and leukemic spread.
Purpose of the Study:
- To summarize current understanding and treatment approaches for BPDCN.
- To highlight the potential of novel targeted therapies in managing this rare neoplasm.
Main Methods:
- Review of existing literature on BPDCN.
- Analysis of treatment guidelines and emerging therapeutic strategies.
Main Results:
- Pediatric patients are typically treated with regimens for high-risk acute lymphoblastic leukemia, including CNS prophylaxis.
- Hematopoietic stem cell transplantation is considered for pediatric cases with relapsed/refractory or high-risk disease at diagnosis.
- The anti-CD123 cytotoxin, recently FDA-approved, demonstrates significant potential in enhancing treatment response rates.
Conclusions:
- BPDCN requires tailored treatment strategies based on age and disease risk.
- Emerging targeted therapies, particularly anti-CD123 agents, offer new hope for improved outcomes in BPDCN patients.
